Loading...
•
Jun 30, 2025
MeiraGTx Q2 2025 Earnings Report
MeiraGTx reported a narrowed quarterly loss with increased service revenue driven by clinical manufacturing services.
Key Takeaways
MeiraGTx posted $3.7M in service revenue for Q2 2025, significantly up from $0.3M YoY, while narrowing its net loss to $38.8M. The company ended the quarter with $32.2M in cash and cash equivalents and continues to advance multiple late-stage programs and regulatory filings.
Service revenue rose to $3.7M, driven by PPQ services for Johnson & Johnson Innovative Medicine
Net loss narrowed to $38.8M from $48.6M YoY
Cash and cash equivalents stood at $32.2M at quarter-end
Weighted average shares outstanding increased to 80.6M from 64.4M YoY
Revenue by Segment
Forward Guidance
MeiraGTx expects to initiate several clinical trials and regulatory filings by year-end 2025, supported by strategic partnerships and internal manufacturing capabilities.
Positive Outlook
- RMAT designation granted for AAV-GAD in Parkinson’s disease
- FDA alignment for pivotal AAV-AQP1 study in radiation-induced xerostomia
- Strong collaboration and funding from Hologen for CNS gene therapies
- Manufacturing capability recognized in U.K. and Ireland inspections
- Advancement of riboswitch platform for in vivo delivery into human trials
Challenges Ahead
- Continued operating and net losses
- High R&D and G&A expenses maintained
- Share dilution from increased outstanding shares
- No license revenue recognized in the quarter
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...